Immunoprecise Common Stock Shares Outstanding vs Total Current Liabilities Analysis

IPA Stock

USD 0.38 0.03 8.57%

Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Common Stock Shares Outstanding and its Total Current Liabilities accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

Common Stock Shares Outstanding vs Total Current Liabilities

Common Stock Shares Outstanding vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Common Stock Shares Outstanding account and Total Current Liabilities. At this time, the significance of the direction appears to have almost identical trend.

The correlation between Immunoprecise Antibodies' Common Stock Shares Outstanding and Total Current Liabilities is 0.91. Overlapping area represents the amount of variation of Common Stock Shares Outstanding that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Common Stock Shares Outstanding and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Common Stock Shares Outstanding of Immunoprecise Antibodies are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Common Stock Shares Outstanding i.e., Immunoprecise Antibodies' Common Stock Shares Outstanding and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.91

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Total Current Liabilities

Total Current Liabilities is an item on Immunoprecise Antibodies balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Immunoprecise Antibodies are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most indicators from Immunoprecise Antibodies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.At present, Immunoprecise Antibodies' Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 0.74, whereas Tax Provision is projected to grow to (1.4 M).

	2021	2022	2023	2024 (projected)
Gross Profit	11.0M	11.6M	12.1M	12.7M
Total Revenue	19.4M	20.7M	24.5M	25.7M

Gross Profit Total Revenue

Immunoprecise Antibodies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Non Currrent Assets Other	Short Long Term Debt Total	Property Plant And Equipment Gross	Short Term Debt	Inventory	Current Deferred Revenue	Intangible Assets
Total Assets		0.9	0.86	0.98	0.68	-0.41	-0.73	0.86	0.69	0.93	0.69	0.88	0.92	-0.26	0.97	-0.16	0.86	0.78	0.79	-0.29	0.59	0.76	0.57	0.85	0.81	0.9
Other Current Liab	0.9		0.9	0.88	0.54	-0.47	-0.56	0.75	0.72	0.78	0.72	0.89	0.85	-0.31	0.85	-0.31	0.79	0.81	0.66	-0.26	0.5	0.57	0.67	0.82	0.84	0.68
Total Current Liabilities	0.86	0.9		0.78	0.67	-0.19	-0.67	0.9	0.49	0.85	0.48	0.94	0.91	-0.33	0.75	-0.33	0.9	0.59	0.77	-0.27	0.66	0.7	0.84	0.9	0.94	0.76
Total Stockholder Equity	0.98	0.88	0.78		0.55	-0.57	-0.62	0.75	0.8	0.86	0.79	0.79	0.83	-0.23	0.98	-0.14	0.74	0.87	0.65	-0.3	0.44	0.64	0.53	0.76	0.73	0.86
Property Plant And Equipment Net	0.68	0.54	0.67	0.55		0.27	-0.96	0.84	0.11	0.81	0.1	0.81	0.87	-0.17	0.62	-0.01	0.9	0.21	0.95	-0.23	0.95	0.98	0.31	0.8	0.73	0.67
Net Debt	-0.41	-0.47	-0.19	-0.57	0.27		-0.19	0.0	-0.93	-0.07	-0.93	-0.13	-0.08	0.07	-0.5	0.11	0.06	-0.87	0.2	0.14	0.33	0.2	-0.18	-0.06	-0.14	-0.16
Retained Earnings	-0.73	-0.56	-0.67	-0.62	-0.96	-0.19		-0.84	-0.17	-0.85	-0.16	-0.78	-0.87	0.26	-0.68	-0.2	-0.89	-0.27	-0.94	0.39	-0.85	-0.98	-0.33	-0.81	-0.69	-0.75
Accounts Payable	0.86	0.75	0.9	0.75	0.84	0.0	-0.84		0.34	0.93	0.33	0.9	0.93	-0.31	0.74	-0.18	0.97	0.44	0.93	-0.16	0.81	0.88	0.59	0.86	0.83	0.84
Cash	0.69	0.72	0.49	0.8	0.11	-0.93	-0.17	0.34		0.38	1.0	0.47	0.43	-0.17	0.75	-0.15	0.3	0.98	0.17	-0.22	0.03	0.16	0.34	0.38	0.46	0.41
Non Current Assets Total	0.93	0.78	0.85	0.86	0.81	-0.07	-0.85	0.93	0.38		0.38	0.88	0.95	-0.27	0.87	-0.11	0.94	0.5	0.91	-0.25	0.73	0.89	0.55	0.88	0.79	0.95
Cash And Short Term Investments	0.69	0.72	0.48	0.79	0.1	-0.93	-0.16	0.33	1.0	0.38		0.46	0.42	-0.13	0.74	-0.15	0.29	0.98	0.16	-0.23	0.02	0.15	0.33	0.37	0.44	0.4
Net Receivables	0.88	0.89	0.94	0.79	0.81	-0.13	-0.78	0.9	0.47	0.88	0.46		0.97	-0.33	0.82	-0.31	0.95	0.58	0.87	-0.19	0.8	0.82	0.66	0.87	0.97	0.77
Common Stock Shares Outstanding	0.92	0.85	0.91	0.83	0.87	-0.08	-0.87	0.93	0.43	0.95	0.42	0.97		-0.33	0.85	-0.22	0.98	0.55	0.93	-0.24	0.84	0.9	0.62	0.94	0.91	0.85
Short Term Investments	-0.26	-0.31	-0.33	-0.23	-0.17	0.07	0.26	-0.31	-0.17	-0.27	-0.13	-0.33	-0.33		-0.25	0.01	-0.3	-0.18	-0.26	-0.11	-0.27	-0.19	-0.29	-0.29	-0.36	-0.26
Other Current Assets	0.97	0.85	0.75	0.98	0.62	-0.5	-0.68	0.74	0.75	0.87	0.74	0.82	0.85	-0.25		-0.09	0.76	0.83	0.7	-0.31	0.5	0.7	0.46	0.76	0.74	0.86
Other Stockholder Equity	-0.16	-0.31	-0.33	-0.14	-0.01	0.11	-0.2	-0.18	-0.15	-0.11	-0.15	-0.31	-0.22	0.01	-0.09		-0.18	-0.18	-0.08	-0.65	-0.24	0.02	-0.39	-0.2	-0.39	-0.12
Total Liab	0.86	0.79	0.9	0.74	0.9	0.06	-0.89	0.97	0.3	0.94	0.29	0.95	0.98	-0.3	0.76	-0.18		0.42	0.97	-0.21	0.87	0.92	0.58	0.91	0.88	0.82
Total Current Assets	0.78	0.81	0.59	0.87	0.21	-0.87	-0.27	0.44	0.98	0.5	0.98	0.58	0.55	-0.18	0.83	-0.18	0.42		0.29	-0.25	0.13	0.27	0.43	0.49	0.56	0.53
Non Current Liabilities Total	0.79	0.66	0.77	0.65	0.95	0.2	-0.94	0.93	0.17	0.91	0.16	0.87	0.93	-0.26	0.7	-0.08	0.97	0.29		-0.16	0.91	0.97	0.38	0.84	0.77	0.78
Non Currrent Assets Other	-0.29	-0.26	-0.27	-0.3	-0.23	0.14	0.39	-0.16	-0.22	-0.25	-0.23	-0.19	-0.24	-0.11	-0.31	-0.65	-0.21	-0.25	-0.16		0.03	-0.25	-0.3	-0.34	-0.18	-0.21
Short Long Term Debt Total	0.59	0.5	0.66	0.44	0.95	0.33	-0.85	0.81	0.03	0.73	0.02	0.8	0.84	-0.27	0.5	-0.24	0.87	0.13	0.91	0.03		0.91	0.35	0.75	0.76	0.6
Property Plant And Equipment Gross	0.76	0.57	0.7	0.64	0.98	0.2	-0.98	0.88	0.16	0.89	0.15	0.82	0.9	-0.19	0.7	0.02	0.92	0.27	0.97	-0.25	0.91		0.34	0.82	0.73	0.79
Short Term Debt	0.57	0.67	0.84	0.53	0.31	-0.18	-0.33	0.59	0.34	0.55	0.33	0.66	0.62	-0.29	0.46	-0.39	0.58	0.43	0.38	-0.3	0.35	0.34		0.71	0.77	0.57
Inventory	0.85	0.82	0.9	0.76	0.8	-0.06	-0.81	0.86	0.38	0.88	0.37	0.87	0.94	-0.29	0.76	-0.2	0.91	0.49	0.84	-0.34	0.75	0.82	0.71		0.84	0.8
Current Deferred Revenue	0.81	0.84	0.94	0.73	0.73	-0.14	-0.69	0.83	0.46	0.79	0.44	0.97	0.91	-0.36	0.74	-0.39	0.88	0.56	0.77	-0.18	0.76	0.73	0.77	0.84		0.71
Intangible Assets	0.9	0.68	0.76	0.86	0.67	-0.16	-0.75	0.84	0.41	0.95	0.4	0.77	0.85	-0.26	0.86	-0.12	0.82	0.53	0.78	-0.21	0.6	0.79	0.57	0.8	0.71

Click cells to compare fundamentals

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.3M	67.0M	93.5M	77.8M	60.0M	63.0M
Other Current Liab	1.8M	3.3M	2.6M	2.3M	1.9M	2.0M
Total Current Liabilities	7.9M	6.1M	9.3M	5.9M	8.1M	8.5M
Total Stockholder Equity	15.1M	56.9M	75.3M	57.8M	33.9M	35.6M
Property Plant And Equipment Net	3.2M	4.1M	3.7M	10.7M	16.7M	17.5M
Net Debt	1.9M	(38.3M)	(27.4M)	(1.0M)	10.2M	10.7M
Retained Earnings	(22.5M)	(29.8M)	(46.5M)	(73.1M)	(100.3M)	(95.3M)
Accounts Payable	1.8M	1.3M	3.9M	2.5M	4.1M	4.3M
Cash	2.6M	41.8M	30.0M	8.3M	3.5M	4.0M
Non Current Assets Total	19.6M	18.1M	56.0M	61.0M	48.5M	50.9M
Cash And Short Term Investments	2.6M	41.8M	30.0M	8.3M	3.5M	4.1M
Net Receivables	3.7M	3.6M	3.4M	3.9M	4.5M	4.7M
Common Stock Shares Outstanding	13.6M	16.5M	19.7M	24.9M	25.6M	26.9M
Liabilities And Stockholders Equity	27.3M	67.0M	93.5M	77.8M	60.0M	63.0M
Other Current Assets	614.0K	2.3M	2.5M	2.6M	1.4M	1.5M
Other Stockholder Equity	3.5M	7.2M	9.6M	10.8M	12.4M	9.3M
Total Liab	12.2M	10.0M	18.2M	20.0M	26.1M	27.4M
Total Current Assets	7.7M	48.9M	37.5M	16.8M	11.5M	6.0M
Non Current Liabilities Total	4.2M	4.0M	8.9M	14.1M	17.9M	18.8M
Non Currrent Assets Other	85.1K	79K	82K	86K	561K	822.8K
Short Long Term Debt Total	4.5M	3.5M	2.5M	7.3M	13.7M	14.4M
Property Plant And Equipment Gross	3.1M	4.1M	9.4M	17.1M	21.5M	22.6M
Accumulated Other Comprehensive Income	(300.2K)	(687K)	(2.5M)	2.6M	2.0M	2.1M
Short Term Debt	2.9M	986K	2.3M	1.1M	1.6M	1.1M
Inventory	818.6K	1.2M	1.6M	2.1M	2.1M	2.2M
Current Deferred Revenue	1.5M	1.1M	1.0M	977K	1.4M	1.4M
Intangible Assets	8.3M	6.1M	32.4M	30.9M	23.6M	15.6M
Common Stock	34.1M	80.1M	114.6M	117.5M	119.8M	125.8M
Net Tangible Assets	(1.0M)	43.1M	23.2M	7.7M	8.9M	12.5M
Net Invested Capital	17.7M	58.5M	76.6M	57.8M	33.9M	39.2M
Net Working Capital	(230.3K)	42.8M	28.2M	10.9M	3.4M	3.2M
Property Plant Equipment	3.1M	4.0M	3.3M	10.4M	12.0M	12.5M
Other Liab	2.6M	1.5M	8.6M	7.9M	9.1M	5.1M
Other Assets	287.6K	163K	476K	437K	393.3K	373.6K
Good Will	7.9M	7.8M	19.7M	19.2M	7.7M	11.8M
Capital Lease Obligations	1.9M	1.9M	1.2M	7.3M	13.7M	14.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:

How To Invest In Immunoprecise

Details

Is Immunoprecise Stock a good investment?

Details

What is Immunoprecise Antibodies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.77)

Revenue Per Share

0.921

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.13)

Return On Equity

(0.64)

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunoprecise Common Stock Shares Outstanding vs Total Current Liabilities Analysis

Common Stock Shares Outstanding vs Total Current Liabilities

Common Stock Shares Outstanding vs Total Current Liabilities Correlation Analysis

Correlation Coefficient

Common Stock Shares Outstanding

Total Current Liabilities

Immunoprecise Antibodies fundamental ratios Correlations

Immunoprecise Antibodies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunoprecise Antibodies fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Total Stockholder Equity	+ 0.98	Total Assets
Other Current Assets	+ 0.98	Total Stockholder Equity
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Current Assets	+ 0.98	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments

Property Plant And Equipment Gross	- 0.98	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net
Non Current Liabilities Total	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.93	Net Debt
Total Liab	- 0.89	Retained Earnings